Mezibe Plus 10 mg and 10 mg, 10 mg and 20 mg, Tablets
PDF Leaflet Revision Date: 29 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunctive therapy for primary hypercholesterolaemia and mixed hyperlipidaemia.
Dosage (summary)
Start at 10/20 mg/day; max 10/80 mg/day for hypercholesterolaemia.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- CYP3A4 inhibitors
- Fibrates
- Gemfibrozil
- Amiodarone
- Verapamil
Contraindications
- Hypersensitivity
- Active liver disease
- Moderate to severe hepatic impairment
- Pregnancy
- Lactation
- Children
Common side effects
- Headache
- Abdominal pain
- Diarrhoea
- Myopathy
- Rhabdomyolysis
Counselling Points
- Take in the evening
- Report muscle pain or weakness
- Avoid grapefruit juice
- Monitor for liver function
Serious warnings
- Risk of myopathy/rhabdomyolysis
- Monitor liver enzymes
- Avoid potent CYP3A4 inhibitors
Important Disclaimer
The Mezibe Plus 10 mg and 10 mg, 10 mg and 20 mg, Tablets professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
